<DOC>
	<DOCNO>NCT02013427</DOCNO>
	<brief_summary>This study design examine brain property placebo response chronic back pain patient . The investigator preliminary data indicating , blind clinical trial study neutral instruction regard treatment , chronic back pain ( CBP ) patient subdivide placebo responder non-responders , difference PREDICTABLE priori , brain activity . The result imply CBP placebo may clinical utility property study human brain imaging technique . In Phase I study , investigator seek identify brain image parameter predict propensity placebo response independent CBP cohort . In Phase II , investigator evaluate interaction placebo response medication treatment individual stratify placebo responder versus non-responders . This research design critically assess neurobiology placebo analgesia chronic pain partially-blind clinical trial .</brief_summary>
	<brief_title>Placebo In Chronic Back Pain - Double-Blind Randomized Control Trial</brief_title>
	<detailed_description>Below detail description study would entail ( word , would expect visit duration study ) . - Visit 1 ( week -2 ) : Pre-treatment screening ( 180 min ) . Participants complete informed consent process evaluate inclusion/exclusion criterion . A medical/pain history physical examination complete participant ask assess current back pain intensity VAS scale ( 0-100mm , pain bad possible pain ) . Participants complete questionnaire return within 2 week baseline MR imaging scan . Blood drawn baseline screen obtain complete blood count , chemistry panel , liver function test . Participants ask discontinue current pain medication 14 day ( 2 week ) prior baseline visit take acetaminophen rescue medication time . - Visit 2 ( week 0 ) : Baseline visit ( 60-90 min ) . Participants complete VAS pain scale , pain designate level change clinical status report , complete battery questionnaire undergo fMRI procedure ( anatomical functional scan ) . Participants randomize one three group : active treatment , placebo , no-treatment group ; do partially blind fashion ( explain ) , medication dispense sufficient quantity next visit . The placebo group receive two placebo capsule bid , standard care group receive one naproxen capsule ( 500mg ) one esomeprazole capsule ( 20 mg ) bid treatment period . The active placebo treatment group double-blinded , mean neither participant researcher know treatment participant receive ( part use identical re-encapsulation study agent ) . The no-treatment group allocation blind , participant study staff aware participant receive study agent . The treatment group participant assign treatment group continue receive rescue medication ( n=20 ) . - Visit 3 ( week 2 ) : End Treatment Period 1/Washout ( 60-90 min ) . All procedure perform described Visit 2 . A set questionnaire administer . Adherence assess pill count , use rescue medication document , participant query side effect experience . Only rescue medication dispense , participant , begin one week washout treatment . - Visit 4 ( week 3 ) : End Washout/Beginning Treatment Period 2 ( 60-90 min ) . All procedure perform described Visit 3 , plus addition brain scan . Adherence assess use rescue medication document , participant query side effect experience . Study medication dispense sufficient quantity next visit . All participant remain treatment assignment Period 1 . - Visit 5 ( week 5 ) : End Treatment Period 2/Washout 2 ( 60-90 min ) . All procedure perform described Visit 3 , addition post-treatment imaging scan . Adherence assess pill count , use rescue medication document , participant query side effect experience . Only rescue medication dispense . - Visit 6 ( week 6 ) : End Washout 2 ( 90 min ) . Participants return complete questionnaire image study conduct . Use rescue medication side effect document . Exit interview conduct time . - Interim period : During week visit , participant data track assistance smart phone/computer application design study . Depending upon preference , research staff download app onto participant ' phone give link use computer ; case participant smart phone easy access computer/internet , study provide him/her smart phone app already instal . Participants give login ask use application twice day right take medication . The app ask participant rate severity pain mood Likert scale , probe whether take medication .</detailed_description>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<criteria>History low back pain minimum 6 month sign symptom radiculopathy : positive straight leg raise test dermatomal radiation and/or myotomal weakness and/or reflex asymmetry ; pain must radiate buttock . Male female , age great than18 year , racial/ethnic restriction . Must Visual Analog Scale ( VAS ) pain score &gt; 50 mm ( 100 mm maximum ) baseline visit ( 0mm = pain , 100 mm = bad pain imaginable ) . Must able read speak English willing read understand instruction well questionnaire . Must generally stable health . Must sign inform consent document complete explanation study document understand purpose study , procedure undertake , possible benefit , potential risk , willing participate . Low back pain associated systemic sign symptom , e.g. , fever , chill . Evidence rheumatoid arthritis , ankylose spondylitis , acute vertebral fracture , fibromyalgia , history tumor back . Other comorbid chronic pain neurological condition . Involvement litigation regard back pain disability claim receive workman 's compensation seek either result low back pain . Diagnosis current depression psychiatric disorder require treatment , diagnosis previous 6 month . Beck Depression Inventory II score &gt; 28 . Use therapeutic dos antidepressant medication ( i.e. , tricyclic depressant , SSRIs , SNRIs ; low dos use sleep may allow ) . Significant medical disease unstable diabetes mellitus , congestive heart failure , coronary peripheral vascular disease , chronic obstructive lung disease , malignancy . History gastrointestinal ulcer past year . History myocardial infarction past year . Uncontrolled hypertension . Renal insufficiency . Allergic , nontolerant , NSAIDs . History aspirinsensitive asthma . Regular use low dose aspirin . Current use recreational drug history alcohol drug abuse . Any change medication back pain last 30 day . High dose opioid prophylaxis , define &gt; 50mg morphine equivalent/day . Any medical condition investigator 's judgment may prevent individual completing study put individual undue risk . In judgment investigator , unable unwilling follow protocol instruction . Evidence poor treatment compliance , judgment investigator . Intraaxial implant ( e.g . spinal cord stimulators pump ) . All exclusion criterion MR safety : metallic implant , brain skull abnormality , tattoo large body part , claustrophobia . Pregnancy , inability use effective form contraception woman childbearing age . Diabetes ( Type I Type II ) . Prohibited Medications : Therapeutic dos antidepressant medication ( i.e. , tricyclic depressant , SSRIs , SNRIs ; low dos use sleep may allow ) . Oral iron supplementation unless approve investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>chronic</keyword>
	<keyword>back</keyword>
	<keyword>pain</keyword>
	<keyword>brain</keyword>
	<keyword>MRI</keyword>
</DOC>